Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Price Target at $443.00

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received an average recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $443.00.

A number of equities analysts have recently issued reports on MEDP shares. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and upped their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and boosted their price target for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective for the company. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, Guggenheim raised their price target on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Medpace news, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at $6,117,943. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the transaction, the insider now directly owns 5,525,959 shares in the company, valued at $2,135,175,298.01. The disclosure for this sale can be found here. In the last ninety days, insiders sold 204,442 shares of company stock worth $82,702,867. Company insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Medpace by 2.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after purchasing an additional 148 shares in the last quarter. Portside Wealth Group LLC raised its holdings in Medpace by 14.8% during the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after purchasing an additional 183 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after buying an additional 2,774 shares during the last quarter. Norden Group LLC grew its position in shares of Medpace by 207.8% in the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock valued at $1,537,000 after buying an additional 3,385 shares during the last quarter. Finally, Retirement Systems of Alabama raised its stake in Medpace by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 62,106 shares of the company’s stock worth $19,037,000 after acquiring an additional 204 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

NASDAQ MEDP opened at $399.20 on Tuesday. The company has a market cap of $12.37 billion, a PE ratio of 40.69, a P/E/G ratio of 1.95 and a beta of 1.40. The firm’s 50 day moving average price is $397.73 and its 200-day moving average price is $335.02. Medpace has a 52-week low of $197.39 and a 52-week high of $421.00.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.27 EPS. On average, analysts forecast that Medpace will post 11.23 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.